PathAI (company)

PathAI, located in Boston, Massachusetts, is a medical technology company that runs a technical pathology program that can provide an efficient and more accurate diagnoses for patients and providers. Additionally, the software is currently working to further assist in research, drug development, global health solutions, and treatments.

PathAI has two primary missions for its AI product: help pathologists make more accurate diagnoses and better predict how patients will respond to a pathologist's recommended therapy based on the characteristics of patient tissue.

PathAI was founded by co-founders Andrew H. Beck and Aditya Khosla with the goal of reducing "error rates, increase accuracy and reproducibility" in pathology. In 2017, the company began partnering with pharmaceutical companies to work on drug development. In 2021, with $165M raised in Series C funding (co-led by D1 Capital Partners and Kaiser Permanente) the company began clinical diagnostics with the acquisition of Poplar, a lab service provider for Poplar Healthcare PLLC. Since then, several industry collaborations have been established with companies such as Roche, LabCorp, and Cleveland Clinic.

Investors include:

D1 Capital Partners

Kaiser Permanente

General Atlantic

General Catalyst

Tiger Global

Bristol Myers Squibb

Merck

Resultantly, the company's clinical research may reach conflicts of interest being a for-profit company including sponsors seeking research and development as noted in the company's publications.

PathAI initially focused on applications in drug development but expanded to the clinical setting in 2021. Their main focuses are translational research is the conventional method of research in which pathologists and data scientists apply existing and new models to process samples. Samples may be interpreted from off-site labs or analyzed on-site. This method of research focuses to "identify new insights on pharmacodynamics, mechanism of action, and patient stratification".

Clinical trial services is a method of analysis used to help identify biomarkers for "patient enrollment, endpoint analysis, and correlative studies in prospective clinical trials". Research organizations access the company's algorithms for slide viewing, reports on interpretable features such as diagnoses or biomarker scores, and other services such as sample processing, staining, scanning, and digitization.

Diagnostic development and deployment is a method of research used to "develop and commercialize AI-powered diagnostics globally and at scale". This includes adding AI models for complementary diagnosis, engaging with sponsors and health authorities, and launching new diagnostics through company labs (and partner labs).

Collaborations include:

Roche pertaining to cancer diagnoses in patient care.

LabCorp's drug development to develop GCLP algorithms for compliant patient stratification and selection.

Cleveland Clinic's application of diagnostic algorithms to patient care.

PathAI's current academic publications cover topics including T-cells (CD8), liver disease (NASH), cancer (HER2, PD-L1, TME):

A model which reproduced all endpoints for NASH resolution and showed granular evidence of fibrosis reduction.

A CD8 classifier paired with PD-L1 status increased biomarker-positive patients 40% over prior PD-L1 studies.

A PD-L1 model which identified 28% additional positive patients from a retrospective analysis on false negatives.

A model which predicted HRD status from H&E-stained slides.PathAI also received news coverage for accepting funding from Danhua Capital for the company's financial ties to the Chinese Communist Party as Commerce Secretary Gina Raimondo's husband's investment in PathAI brought light to the fact.